Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes

S Chen, R Knox, AD Lewis, F Friedlos, P Workman, PS Deng, M Fung, D Ebenstein, K Wu and TM Tsai

Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA.

NAD(P):quinone acceptor oxidoreductase (quinone reductase) (DT- diaphorase, EC 1.6.99.2) is involved in the process of reductive activation of cytotoxic antitumor quinones and nitrobenzenes. In this study, we initially examined the relative abilities of mouse, rat, and human quinone reductases to reduce two prodrugs, CB 1954 [5-(aziridin-1- yl)-2,4-dinitrobenzamide] and EO9 [5-(1-aziridinyl)-3-(hydroxymethyl)-2- (3-hydroxy-1-propenyl)-1- methyl-1H-indole-4,7-dione]. By using Escherichia coli-expressed quinone reductases and evaluating them under identical conditions, we confirmed previous finding showing that the human enzyme is not as effective as the rat enzyme in reducing CB 1954 and EO9, although the two enzymes have similar NAD(P)H-menadione reductase activities. Interestingly, although the amino acid sequence of mouse quinone reductase is more homologous to that of the rat enzyme, we found that the mouse enzyme behaves similarly to the human enzyme in its ability to reduce these compounds and to generate drug- induced DNA damage. To determine the region of quinone reductase that is responsible for the catalytic differences, two mouse-rat chimeric enzymes were generated. MR-P, a chimeric enzyme that has mouse amino- terminal and rat carboxy-terminal segments of quinone reductase, was shown to have catalytic properties resembling those of rat quinone reductase, and RM-P, a chimeric enzyme that has rat amino-terminal and mouse carboxyl-terminal segments of quinone reductase, was shown to have catalytic properties resembling those of mouse quinone reductase. In addition, MR-P and RM-P were found to be inhibited by flavones with Ki values similar to those for rat and mouse quinone reductases, respectively. Based on these results, we propose that the carboxyl- terminal portion of the enzyme plays an important role in the reduction of cytotoxic drugs and the binding of flavones.

Volume 47, Issue 5, pp. 934-939, 05/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. Chao, Z.-F. Zhang, J. Berthiller, P. Boffetta, and M. Hashibe NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Pro187Ser Polymorphism and the Risk of Lung, Bladder, and Colorectal Cancers: a Meta-analysis. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 979 - 987. [Abstract] [Full Text] [PDF]

				K. E. Reinicke, E. A. Bey, M. S. Bentle, J. J. Pink, S. T. Ingalls, C. L. Hoppel, R. I. Misico, G. M. Arzac, G. Burton, W. G. Bornmann, et al. Development of {beta}-Lapachone Prodrugs for Therapy Against Human Cancer Cells with Elevated NAD(P)H:Quinone Oxidoreductase 1 Levels Clin. Cancer Res., April 15, 2005; 11(8): 3055 - 3064. [Abstract] [Full Text] [PDF]

				S. Y. Sharp, L. R. Kelland, M. R. Valenti, L. A. Brunton, S. Hobbs, and P. Workman Establishment of an Isogenic Human Colon Tumor Model for NQO1 Gene Expression: Application to Investigate the Role of DT-Diaphorase in Bioreductive Drug Activation In Vitro and In Vivo Mol. Pharmacol., November 1, 2000; 58(5): 1146 - 1155. [Abstract] [Full Text]

				T. Naoe, K. Takeyama, T. Yokozawa, H. Kiyoi, M. Seto, N. Uike, T. Ino, A. Utsunomiya, A. Maruta, I. Jin-nai, et al. Analysis of Genetic Polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese Patients with Therapy-related Leukemia/Myelodysplastic Syndrome and de novo Acute Myeloid Leukemia Clin. Cancer Res., October 1, 2000; 6(10): 4091 - 4095. [Abstract] [Full Text]

				R. J. Knox, T. C. Jenkins, S. M. Hobbs, S. Chen, R. G. Melton, and P. J. Burke Bioactivation of 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by Human NAD(P)H Quinone Oxidoreductase 2: A Novel Co-substrate-mediated Antitumor Prodrug Therapy Cancer Res., August 1, 2000; 60(15): 4179 - 4186. [Abstract] [Full Text]

				J. J. Pink, S. M. Planchon, C. Tagliarino, M. E. Varnes, D. Siegel, and D. A. Boothman NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of beta -Lapachone Cytotoxicity J. Biol. Chem., February 25, 2000; 275(8): 5416 - 5424. [Abstract] [Full Text] [PDF]

				H. Chen, A. Lum, A. Seifried, L. R. Wilkens, and L. L. Marchand Association of the NAD(P)H:quinone Oxidoreductase 609C{->}T Polymorphism with a Decreased Lung Cancer Risk Cancer Res., July 1, 1999; 59(13): 3045 - 3048. [Abstract] [Full Text] [PDF]

				S. Chen, R. Knox, K. Wu, P. S.-K. Deng, D. Zhou, M. A. Bianchet, and L. M. Amzel Molecular Basis of the Catalytic Differences among DT-diaphorase of Human, Rat, and Mouse J. Biol. Chem., January 17, 1997; 272(3): 1437 - 1439. [Abstract] [Full Text] [PDF]

				G. N. Kumar, E. Dubberke, A. D. Rodrigues, E. Roberts, and J. F. Dennisen Identification of Cytochromes P450 Involved in the Human Liver Microsomal Metabolism of the Thromboxane A2 Inhibitor Seratrodast (ABT-001) Drug Metab. Dispos., January 1, 1997; 25(1): 110 - 115. [Abstract] [Full Text]

				M. Faig, M. A. Bianchet, P. Talalay, S. Chen, S. Winski, D. Ross, and L. M. Amzel Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: Species comparison and structural changes with substrate binding and release PNAS, March 28, 2000; 97(7): 3177 - 3182. [Abstract] [Full Text] [PDF]